IRTC
HealthcareiRhythm Technologies, Inc.
$184.39
+$9.17 (+5.23%)
Jan 5, 2026
Price History (1Y)
Analysis
iRhythm Technologies, Inc. is a healthcare company in the medical devices industry with a significant presence, boasting 2000 employees and a market capitalization of $5.94 billion. The company's scale is further underscored by its revenue, which totals $702.57 million on a trailing twelve-month basis. The company's financial health reveals mixed results. Despite a high gross margin of 70.3%, iRhythm Technologies incurs significant losses, with a net income of -$51.463 million and an EBITDA loss of -$41.065 million over the same period. The company's returns on equity and assets are negative, at -53.1% and -3.1%, respectively. Its balance sheet is also noteworthy, featuring $733.01 million in debt against $565.21 million in cash. Valuation metrics indicate that iRhythm Technologies' stock price may be influenced by its relatively low price-to-sales ratio of 8.46 and a negative forward P/E ratio of -615.97. Revenue growth has been strong, increasing by 30.7% year-over-year, although earnings growth is not available for comparison. The company does not currently pay dividends, with a payout ratio of 0.0%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About iRhythm Technologies, Inc.
iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days; Zio XT System, a prescription-only remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and Zio ECG Utilization Software System, which supports the capture and analysis of ECG data. In addition, the company offers Zio AT System, a prescription-only remote ECG monitoring system, which consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days, as well as incorporates the Zio AT wireless gateway to provide connectivity between the patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. iRhythm Technologies, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Visit website →Key Statistics
- Market Cap
- $5.94B
- P/E Ratio
- N/A
- 52-Week High
- $212.00
- 52-Week Low
- $86.99
- Avg Volume
- 436.83K
- Beta
- 1.12
Company Info
- Industry
- Medical Devices
- Exchange
- NMS
- Country
- United States
- Employees
- 2,000